Overview: Cytology Body Fluids Panel
Introduction: The Cytology Body Fluids Panel is a diagnostic tool designed to analyze body fluid cytology using sterile fluid samples. In India, body fluid cytology (pleural, peritoneal, pericardial, CSF) is crucial for detecting malignancy (metastatic carcinoma, lymphoma), infection (TB, bacterial), or inflammation, with high yield in cancer-related effusions. High burden from underutilization in rural hospitals, limited cytopathology expertise, delayed diagnosis leading to missed malignancy or untreated infection. Per histopathology practices aligned with ICMR guidelines, the test employs microscopy for cell count, type, cytology, protein over 1-2 days with high specificity, valuable for effusion workup. This diagnostic falls under fluid analysis and targets patients with unexplained effusion, ascites, or pleural fluid, addressing accurate detection to guide further investigation (biopsy, culture). With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its fluid-based approach ensures reliable cellular analysis.
Other Names: Cyto Fluid Pnl.
FDA Status: FDA approved, CLIA certified for histopathology, compliant with 2025 standards.
Historical Milestone: Body fluid cytology standard; in India, key in oncology and TB workup.
Purpose: The test assesses 4 parameters including cell count and cytology to guide body fluid evaluation, detect malignancy/infection, inform management.
Test Parameters: 1. Cell Count, 2. Cell Type, 3. Cytology, 4. Protein.
Pretest Condition: No fasting required; patients should report effusion symptoms or fluid accumulation.
Specimen: 5 mL body fluid in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate processing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for cytology).
Medical History: Patients should provide details on effusion cause (TB, malignancy, heart failure), symptoms, prior taps.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed fluid abnormalities including malignancy, benefits of early detection, and minimal discomfort from fluid collection.
Procedural Considerations: The test involves sample processing using microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cellularity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal cytology indicates malignancy or infection, necessitating specialist input. Normal may require follow-up.
Specialist Consultation: Pulmonologists or oncologists should be consulted for management.
Additional Supporting Tests: Culture, ADA, LDH for confirmation.
Test Limitations: May miss low-cellularity malignancy; comprehensive approach required.
References: Indian Journal of Chest Diseases 2024, Fluid Cytology Studies India 2023.
